Key result
In vitro studies show that andexanet alfa provides near full reversal of unfractionated heparin, reversing anti-factor Xa activity and neutralizing anticoagulant effects.
Why the study?
Does andexanet alfa reverse the anticoagulant effects of unfractionated heparin in vitro?
Does andexanet alfa reverse the anticoagulant effects of unfractionated heparin in vitro?
Answers are grounded in this paper and cite their sources.
Andexanet alfa shows potential as an alternative to protamine for the reversal of unfractionated heparin based on in vitro evidence.
The recent shortage of protamine prompted an investigation of alternatives for reversal of unfractionated heparin. Heparin is an anticoagulant utilized in the hospital setting. Available options for anticoagulation include direct oral anticoagulants, vitamin K antagonists, thrombin inhibitors, low-molecular-weight heparins, and heparin. Protamine is the approved reversal agent for heparin with few alternatives under investigation. Although andexanet was designed as an antidote for apixaban and rivaroxaban, in vitro studies show that in a dose-dependent technique, andexanet had near full reversal of heparin, reversed anti-factor Xa activity, and neutralized anticoagulant effects of activated partial thromboplastin time and thrombin time induced by heparin.
No takes yet. Share an insight, caveat, or question.
Maneno et al. (2020) conducted a review in Reversal of unfractionated heparin. Andexanet alfa vs. Protamine was evaluated on Reversal of heparin, anti-factor Xa activity, activated partial thromboplastin time, and thrombin time. In vitro studies show that andexanet alfa provides near full reversal of unfractionated heparin, reversing anti-factor Xa activity and neutralizing anticoagulant effects.
Synapse has enriched 10 related papers. Consider them for comparative context: